The fear factor in health fundraising

Collier, Roger
September 2010
CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, p1294
Academic Journal
The article presents a reprint of an article "The fear factor in health fundraising," by Roger Collier, which appeared on the web site www.cmaj.ca. It discusses the implications of using advertising in fundraising to combat various illnesses, citing an advertisement which depicts a boy facing above the surface of water with a tagline on cystic fibrosis (CF). It mentions that this ad may lead to fallacy, fear, or damage, which June Pierotti of Canadian Cystic Fibrosis Foundation negates.


Related Articles

  • Family of girl with cystic fibrosis to walk m fundraiser. Collier, Jessica // Adirondack Daily Enterprise;5/22/2010, Vol. 117 Issue 121, pA1 

    The article reports on the effort of a local family in Tupper Lake, New York, who has a daughter with cystic fibrosis, to join a walk to raise funds to find a cure for the disease.

  • Paddling for a Cure. Lovering, Sharon // Braille Forum;Jul2013, Vol. 52 Issue 1, p22 

    The article features Jose Tamayo, a blind man from Miami, Florida who participated in a 65-mile canoe trip from Fort Meade to Arcadia to raise money to find new treatment for cystic fibrosis (CF). Topics include how Tamayo lost his sight in 2004 due to retinitis pigmentosa and his interest in...

  • Synteract and Mpex Pharmaceuticals Team Up for Cystic Fibrosis Walk and Cure.  // Biomedical Market Newsletter;5/17/2011, p276 

    The article focuses on the collaboration of Synteract Inc. and Mpex Pharmaceuticals Inc. to support the fundraising event "Great Strides: Taking Steps to Cure Cystic Fibrosis" conducted by Cystic Fibrosis (CF) Foundation held in San Diego, California in May 2011. It mentions that the companies'...

  • New drug for cystic fibrosis shows promise.  // Modern Medicine;Feb95, Vol. 63 Issue 2, p56 

    Presents an abstract of the article `Effect of Aerosolized Recombitant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis by H.J. Fuchs, D.S. Borowitz, et al from the periodical `The New England Journal of Medicine,' dated September 8,...

  • Cystic fibrosis therapy, detection improving.  // Newsweek;5/12/1986, Vol. 107 Issue 19, p69 

    Cystic fibrosis is one of the cruelest and most common genetically transmitted illnesses in the US, with more than 30,000 sufferers at any given time. Now, however, improvements in treatments are extending the lives of cystic fibrosis patients, and recent developments in biotechnology are...

  • Liberated lungs.  // New Scientist;8/21/93, Vol. 139 Issue 1887, p11 

    Reports on the recommendation for the approval of the pulmozyme drug by the Pulmonary-Allergy Drugs Advisory Committee to the Food and Drug Administration. Treatment for cystic fibrosis; Improvement of lung function; Alleviation of lung symptoms; Side effects.

  • Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis. Ramsey, Bonnie W.; Dorkin, Henry L.; Eisenberg, Jay D.; Gibson, Ronald L.; Harwood, Ivan R.; Kravitz, Richard M.; Schidlow, Daniel V.; Wilmott, Robert W.; Astley, Susan J.; McBurnie, Mary Ann; Wentz, Kim; Smith, Arnold L. // New England Journal of Medicine;6/17/93, Vol. 328 Issue 24, p1740 

    Background: Direct aerosol delivery of aminoglycosides such as tobramycin to the lower airways of patients with cystic fibrosis may control infection with Pseudomonas aeruginosa and improve pulmonary function, with low systemic toxicity. We conducted a randomized crossover study to evaluate the...

  • Closing in on cystic-fibrosis. Cowley, Geoffrey // Newsweek;5/3/1993, Vol. 121 Issue 18, p56 

    Reports that on April 17, a 23-year-old man with advanced cystic fibrosis became the first patient to receive a treatment aimed at correcting cystic-fibrosis, the fatal respiratory disorder, at its source. In an audacious experiment, doctors at the National Heart, Lung and Blood Institute...

  • Drug disposition in cystic fibrosis. Rey, E.; Tréluyer, J-M.; Pons, G.; Tréluyer, J M // Clinical Pharmacokinetics;1998, Vol. 35 Issue 4, p313 

    There are many pathological changes in patients with cystic fibrosis (CF) which can lead to alterations in drug disposition. Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered. Plasma protein binding for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics